Sacituzumab Earns Regular FDA Approval for TNBC - NCI

Sacituzumab govitecan (Trodelvy) now has regular FDA approval for people with locally advanced or metastatic triple-negative breast cancer (TNBC), including those with brain metastases. The update follows last year’s accelerated approval of the drug for people with TNBC.

Cureus Advancements in the Treatment of Triple-Negative Breast

Sacituzumab Earns Regular FDA Approval For TNBC NCI

Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic

Sacituzumab Earns Regular FDA Approval for TNBC - NCI

Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic

Sacituzumab Earns Regular FDA Approval For TNBC NCI

Biomolecules, Free Full-Text

FDA Approvals - Cancer Currents Blog - NCI

Pharmaceutics, Free Full-Text

Mission Mountain Wilderness

Sacituzumab govitecan in previously treated hormone receptor

Targeting Triple-negative Breast Cancer

Trodelvy for the Treatment of Advanced Triple-Negative Breast Cancer

Recent advances in targeted strategies for triple-negative breast cancer, Journal of Hematology & Oncology

Trodelvy Any Chance Against Dato-DXd and Enhertu.pdf